• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

含载脂蛋白B的脂蛋白与动脉粥样硬化性心血管疾病

Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease.

作者信息

Shapiro Michael D, Fazio Sergio

机构信息

Center for Preventive Cardiology, Knight Cardiovascular Institute, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA.

出版信息

F1000Res. 2017 Feb 13;6:134. doi: 10.12688/f1000research.9845.1. eCollection 2017.

DOI:10.12688/f1000research.9845.1
PMID:28299190
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5310383/
Abstract

Cholesterol-rich, apolipoprotein B (apoB)-containing lipoproteins are now widely accepted as the most important causal agents of atherosclerotic cardiovascular disease. Multiple unequivocal and orthogonal lines of evidence all converge on low-density lipoprotein and related particles as being the principal actors in the genesis of atherosclerosis. Here, we review the fundamental role of atherogenic apoB-containing lipoproteins in cardiovascular disease and several other humoral and parietal factors that are required to initiate and maintain arterial degeneration. The biology of foam cells and their interactions with high-density lipoproteins, including cholesterol efflux, are also briefly reviewed.

摘要

富含胆固醇、载脂蛋白B(apoB)的脂蛋白如今已被广泛认为是动脉粥样硬化性心血管疾病最重要的致病因素。多条明确且相互独立的证据都指向低密度脂蛋白及相关颗粒是动脉粥样硬化发生过程中的主要参与者。在此,我们综述了致动脉粥样硬化的含apoB脂蛋白在心血管疾病中的基础作用,以及启动和维持动脉退变所需的其他几个体液和壁层因素。还简要综述了泡沫细胞的生物学特性及其与高密度脂蛋白的相互作用,包括胆固醇流出。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c5d/5310383/0baf4cd2ac05/f1000research-6-10615-g0000.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c5d/5310383/0baf4cd2ac05/f1000research-6-10615-g0000.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c5d/5310383/0baf4cd2ac05/f1000research-6-10615-g0000.jpg

相似文献

1
Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease.含载脂蛋白B的脂蛋白与动脉粥样硬化性心血管疾病
F1000Res. 2017 Feb 13;6:134. doi: 10.12688/f1000research.9845.1. eCollection 2017.
2
The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity.富含胆固醇的载脂蛋白B脂蛋白的动脉潴留在动脉粥样硬化发病机制中的核心作用:简单性的胜利。
Curr Opin Lipidol. 2016 Oct;27(5):473-83. doi: 10.1097/MOL.0000000000000330.
3
Pitavastatin: novel effects on lipid parameters.匹伐他汀:对血脂参数的新作用。
Atheroscler Suppl. 2011 Nov;12(3):277-84. doi: 10.1016/S1567-5688(11)70887-X.
4
[Front line of oxidized lipoproteins: role of oxidized lipoproteins in atherogenesis and cardiovascular disease risk].[氧化型脂蛋白的前沿领域:氧化型脂蛋白在动脉粥样硬化形成及心血管疾病风险中的作用]
Rinsho Byori. 2010 Jun;58(6):622-30.
5
Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100.确定含载脂蛋白B100的大、小脂蛋白的致动脉粥样硬化性。
J Clin Invest. 2000 Dec;106(12):1501-10. doi: 10.1172/JCI10695.
6
Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations.中密度和低密度脂蛋白亚组分的异质性特征。
Clin Biochem. 2013 Oct;46(15):1509-15. doi: 10.1016/j.clinbiochem.2013.06.021. Epub 2013 Jul 2.
7
Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.致动脉粥样硬化的致密低密度脂蛋白。病理生理学与新治疗方法。
Eur Heart J. 1998 Feb;19 Suppl A:A24-30.
8
Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?为什么非高密度脂蛋白胆固醇比低密度脂蛋白胆固醇更能作为血管疾病风险的标志物?
J Clin Lipidol. 2010 May-Jun;4(3):152-5. doi: 10.1016/j.jacl.2010.03.005. Epub 2010 Mar 18.
9
Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux.载脂蛋白 B-100 和载脂蛋白 A-II 动力学作为细胞胆固醇流出的决定因素。
J Clin Endocrinol Metab. 2012 Sep;97(9):E1658-66. doi: 10.1210/jc.2012-1522. Epub 2012 Jun 28.
10
Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.利用稳定同位素研究人类载脂蛋白A-I与载脂蛋白B-48和B-100动力学之间的相互关系。
Arterioscler Thromb Vasc Biol. 2004 Sep;24(9):1703-7. doi: 10.1161/01.ATV.0000137975.14996.df. Epub 2004 Jul 8.

引用本文的文献

1
A model based on artificial intelligence for the prediction, prevention and patient-centred approach for non-communicable diseases related to metabolic syndrome.一种基于人工智能的模型,用于预测、预防与代谢综合征相关的非传染性疾病并采用以患者为中心的方法。
Eur J Public Health. 2025 Aug 1;35(4):642-649. doi: 10.1093/eurpub/ckaf098.
2
The Acari Hypothesis, VII: accounting for the comorbidity of allergy with other contemporary medical conditions, especially metabolic syndrome.螨类假说,VII:解释过敏与其他当代医学病症(尤其是代谢综合征)的共病现象。
Front Allergy. 2025 Mar 27;6:1537467. doi: 10.3389/falgy.2025.1537467. eCollection 2025.
3

本文引用的文献

1
[Atherogenic modification of low-density lipoproteins].[低密度脂蛋白的致动脉粥样硬化修饰]
Biomed Khim. 2016 May;62(4):391-402. doi: 10.18097/PBMC20166204391.
2
The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity.富含胆固醇的载脂蛋白B脂蛋白的动脉潴留在动脉粥样硬化发病机制中的核心作用:简单性的胜利。
Curr Opin Lipidol. 2016 Oct;27(5):473-83. doi: 10.1097/MOL.0000000000000330.
3
Disturbed Laminar Blood Flow Vastly Augments Lipoprotein Retention in the Artery Wall: A Key Mechanism Distinguishing Susceptible From Resistant Sites.
High-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure?
动脉粥样硬化性心血管疾病中的高敏C反应蛋白:测还是不测?
US Cardiol. 2025 Mar 21;19:e06. doi: 10.15420/usc.2024.25. eCollection 2025.
4
Lipids dysregulation in diseases: core concepts, targets and treatment strategies.疾病中的脂质失调:核心概念、靶点与治疗策略。
Lipids Health Dis. 2025 Feb 21;24(1):61. doi: 10.1186/s12944-024-02425-1.
5
A whole-animal phenotypic drug screen identifies suppressors of atherogenic lipoproteins.一项全动物表型药物筛选鉴定出致动脉粥样硬化脂蛋白的抑制剂。
bioRxiv. 2025 Jan 16:2024.11.14.623618. doi: 10.1101/2024.11.14.623618.
6
John Yudkin's hypothesis: sugar is a major dietary culprit in the development of cardiovascular disease.约翰·尤德金的假说:糖是心血管疾病发展过程中主要的饮食致病因素。
Front Nutr. 2024 Jul 4;11:1407108. doi: 10.3389/fnut.2024.1407108. eCollection 2024.
7
The Predictive Value of Atherogenic Index of Plasma, Non- High Density Lipoprotein Cholesterol (Non-HDL-C), Non-HDL-C/HDL-C, and Lipoprotein Combine Index for Stroke Incidence and Prognosis in Maintenance Hemodialysis Patients.载脂蛋白 B/载脂蛋白 A1、非高密度脂蛋白胆固醇(Non-HDL-C)、非高密度脂蛋白胆固醇/高密度脂蛋白胆固醇(Non-HDL-C/HDL-C)和脂蛋白组合指数对维持性血液透析患者卒中发生和预后的预测价值。
Clin Interv Aging. 2024 Jul 4;19:1235-1245. doi: 10.2147/CIA.S461150. eCollection 2024.
8
Evolving Concepts of the SCORE System: Subtracting Cholesterol from Risk Estimation: A Way for a Healthy Longevity?SCORE系统的演变概念:从风险评估中减去胆固醇:实现健康长寿的一种方式?
Life (Basel). 2024 May 24;14(6):679. doi: 10.3390/life14060679.
9
Macrophage-based therapeutic approaches for cardiovascular diseases.基于巨噬细胞的心血管疾病治疗方法。
Basic Res Cardiol. 2024 Feb;119(1):1-33. doi: 10.1007/s00395-023-01027-9. Epub 2024 Jan 3.
10
Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis.同一枚硬币的两面:非酒精性脂肪性肝病与动脉粥样硬化。
Vascul Pharmacol. 2024 Mar;154:107249. doi: 10.1016/j.vph.2023.107249. Epub 2023 Dec 7.
紊乱的层流极大地增加脂蛋白在动脉壁的潴留:区分易损部位和抗性部位的关键机制。
Arterioscler Thromb Vasc Biol. 2015 Sep;35(9):1928-35. doi: 10.1161/ATVBAHA.115.305874. Epub 2015 Jul 16.
4
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.依折麦布联合他汀类药物治疗急性冠脉综合征。
N Engl J Med. 2015 Jun 18;372(25):2387-97. doi: 10.1056/NEJMoa1410489. Epub 2015 Jun 3.
5
Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study.高密度脂蛋白胆固醇外排能力与冠心病事件发生的相关性:一项前瞻性病例对照研究。
Lancet Diabetes Endocrinol. 2015 Jul;3(7):507-13. doi: 10.1016/S2213-8587(15)00126-6. Epub 2015 May 27.
6
Targeting PCSK9 for therapeutic gains.靶向前蛋白转化酶枯草溶菌素9以获得治疗益处。
Curr Atheroscler Rep. 2015 Apr;17(4):499. doi: 10.1007/s11883-015-0499-4.
7
HDL cholesterol efflux capacity and incident cardiovascular events.高密度脂蛋白胆固醇流出能力与心血管事件的发生
N Engl J Med. 2014 Dec 18;371(25):2383-93. doi: 10.1056/NEJMoa1409065. Epub 2014 Nov 18.
8
Effects of extended-release niacin with laropiprant in high-risk patients.烟酸缓释剂联合拉罗匹仑在高危患者中的作用。
N Engl J Med. 2014 Jul 17;371(3):203-12. doi: 10.1056/NEJMoa1300955.
9
Unraveling the complexities of the HDL lipidome.解析高密度脂蛋白脂质组的复杂性。
J Lipid Res. 2013 Nov;54(11):2950-63. doi: 10.1194/jlr.R036095. Epub 2013 Mar 30.
10
Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks.胆固醇外排增加与心血管事件风险增加呈矛盾关联。
Arterioscler Thromb Vasc Biol. 2013 Jul;33(7):1696-705. doi: 10.1161/ATVBAHA.113.301373. Epub 2013 Mar 21.